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Abstract 
PD-L1 expression and TMB enrich for patients that respond to checkpoint blockade, but these evaluations are only a component of the entire story. Recently, our lab reported that evaluation of specific cell-cell relationships provided a powerful biomarker for overall survival in 
patients with HPV- head and neck cancer (HNSCC). However, the areas selected for analysis were operator selected “hot spots”. This approach introduces the potential for unconscious bias in the selection process. To address this, we have sought to perform whole slide 
evaluations of sections to compare with hot spot analysis. This study is a preliminary report applying a novel set of fluorophores and filters that allow the visualization of seven colors on a whole slide.  
Tissue samples included pellets of cultured lymphocytes and tumor specimens. A sample of the cultured lymphocytes that were fixed and embedded were analyzed by flow cytometry for immune markers. Formalin-fixed paraffin embedded (FFPE) sections were stained with 
antibodies for CD8, CD68, FoxP3, PD-1, PD-L1, cytokeratin and DAPI. PerkinElmer Opal reagents were used to identify markers and included standard and a new set of fluorophores that included Opal 480, 520, 570, 620, 690, and 780. Slides were imaged using a new scanning 
approach on a Vectra Polaris (PerkinElmer, Inc, Waltham, MA).  
Preliminary comparison of cells that were used to produce FFPE blocks by flow cytometry and multiplex IHC provided similar results for some markers. Determining optimal staining, exposure times and thresholds for analysis for this new method needs work, but the potential 
exists for effective evaluation of a whole slide with 7 different markers.     
Our preliminary results provide reason to be optimistic that this approach can assess 7 colors in a whole slide. Whole sections labelled with 7 colors and spectrally unmixed supports deeper analysis of immune-biology on multiple scales, including re-analysis of spatial metrics 
based on emerging hypotheses about how cellular and expression distributions relate to disease progression and response to therapy.  
Steps for whole slide analysis: 
 
1. Scan tissue slide in Vectra Polaris 
scanner (Akoya Bioscience, 
formerly PerkinElmer). 
2. Phenochart Multiband software 
shows the images in a qpTIFF file 
format with the unmixed 7 colors. 
3. Select different areas on the tissue 
slide with the algorithm 
development stamp (925 µm X 
694 µm). Shown as red boxes in 
the mIHC image (Center). 
4. Open the images selected in 
InForm Multiband software to 
build an algorithm with the 
following steps: tissue 
segmentation, adaptive cell 
segmentation, phenotyping and 
scoring. 
5. Select in Phenochart Multiband 
with the drawing tool the region of 
interest (ROI) for analysis. All ROIs 
regions will get tiled by the 
software (blue grid on the mIHC 
image) 
6. With InForm Multiband the 
algorithm developed will be used 
in the batch analysis tab to run all 
the images tiled in the qpTIFF 
format.  
7. All data for the tiled images 
analyzed will be saved as a txt file 
format.  
 
 The NSCLC slide was tiled into 126 
images. Total area analyzed was 
81mm2.  The 7 colors analysis for 
the whole slide took approx. 3 
hours. 
 The new software has an 
application to extract the 
autofluorescence of the image, 
and represents a big improvement 
in whole slide analysis. 
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CONCLUSIONS 
 
The new Vectra Polaris technology and software coupled 
with Opal reagents provides a fast and powerful method to 
evaluate seven markers on a whole slide 
 
• Whole slide analysis capability - including spatial analysis 
 
• Eliminates bias of the ROI selection 
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FoxP3+ in a 30 microns  
radii of CD8+ cells 
mIHC    Non-Small Cell Lung Cancer (NSCLC) 
 DAPI  CD8  CD68  FoxP3  PD1  Cytokeratin  PDL1 
Composite 7 colors unmixed in qpTIFF image 
CD8   Opal 570 PD1   Opal 620 
PDL1   Opal 520 CD68   Opal 690 
FoxP3   Opal 480 Cytokeratin   Opal 780 
Fluorescence multiplex immunohistochemistry (mIHC) image of a 
NSCLC. The image can be visualized in Phenochart Multiband at 
20X and 40X enabling zoom in/out. There is an option to look at 
the distribution of the different markers on the whole slide by 
turning on/off different channels. In the image above, red boxes 
show the areas used for algorithm development. The blue grids 
show the area that was selected for analysis. The enlarged image 
to the left is identified by the Yellow. Single expression images for 
each marker is also shown.  
Heat maps showing the immune profile 
of the whole sllide mIHC analysis 
Contact information: 
Carmen Ballesteros-Merino, PhD 
Research Scientist 
Carmen.Ballesteros-Merino@providence.org 
T Cell pellet 
Distribution patterns for PD-L1 expression on tumor cells and 
relationships of PD-L1+ tumor with other cell types across the 
entire NSCLC section. (Pearson Correlation analysis) 
r = - 0.19 
p = 0.03 (*)  
r = - 0.117 
p = 0.19 (ns)  
r = - 0.37 
p < 0.0001 (****)  
r = 0.01 
p = 0.89 (ns)  
Multiplex IHC technology provides unprecedented opportunities to investigate tissues. However, there are weaknesses in the 
way cells are enumerated. In an attempt to standardize and better understand best practices for evaluating T cell populations 
and expression of activation markers, a T cell Activation Marker Proficiency Panel (TAMPP) has been initiated. Populations of 
human T cells, extensively characterized by FACS, have been prepared into cell blocks. Slides will be sent out containing sections 
of the characterized T cells for participating labs to perform multiplex IHC, analyze and return results. Results will be 
summarized, site ID blinded and data shared, along with FACS phenotypes, with the participating labs. This academic-based 
collaboration is open to participation by all groups (academic & commercial) using any multiplex technology with results 
prepared for publication. For more info email TAMPP@FoxLab.org 
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